Intravenous ferric carboxymaltose versus iron sucrose in iron deficiency anemia of pregnancy

Parikh, Aneri; Agarwal, Shonali

doi:10.18231/j.ijogr.2022.003

Cited by 3 publications

(7 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study done by Khatun F et al [10] , they found that the adverse reactions was lower among patients of FCM than iron sucrose. In a study done by Parikh A et al [11] , the adverse events were all mild and quickly reversible and mostly restricted to local reaction at the infusion site in both the treatment groups. These findings are comparable with the findings of the present study.…”

Section: Discussionmentioning

confidence: 84%

“…40% and 44% of the study participants in group A and group B had Moderate degree of anaemia respectively. In a study done by Parikh A et al [11] , 32% patients in the FCM group and 62% in Iron sucrose group had mild degree of anaemia.…”

Section: Discussionmentioning

confidence: 91%

“…The association was found to be statistically significant between the mean Ferritin values pre-treatment, 3 rd and 6 th week follow-up post treatment and the 2 groups of study participants. In a study done by Parikh A et al [11] , they found that increment in the mean haemoglobin values were slightly more in the patients treated with FCM as compared to iron sucrose. Also, Serum ferritin level increased in both treatment modalities but was more in patient treated with FCM.…”

Section: Discussionmentioning

confidence: 94%

See 2 more Smart Citations

Comparative study on intravenous iron sucrose versus intravenous ferric carboxymaltose in the management of iron deficiency anaemia in pregnancy in a tertiary care hospital, Bengaluru

A¹,

MN²,

N³

2023

Int. J. Clin. Obstet. Gynaecol.

View full text Add to dashboard Cite

Background: Iron deficiency is the most common nutritional deficiency worldwide; it affects 1.6 billion people Iron deficiency (ID) and iron deficiency anemia (IDA) are often encountered in the general population, particularly among children and women with abnormal uterine bleeding (AUB) and during pregnancy as well as postpartum period Intravenous (IV) iron replacement can deliver the total amount of required iron over a short period. Currently, the most commonly used IV iron formulations are iron sucrose (IS) and ferric carboxymaltose (FCM) [4][5][6]. Iron sucrose does not require test dose and is safe. Ferric carboxymaltose (FCM) is the latest I.V. iron formulation which can be used at high doses and allows rapid administration (up to 1000 mg in a single dose infused in 15 minutes) The present study was a comparative study of parenteral iron therapy (intravenous iron sucrose versus intravenous ferric carboxymaltose in the management of iron deficiency anaemia in pregnancy. Methods: In the present study, 50 pregnant women with IDA were randomly distributed into two groups of 25 each. Group -A: 25 receiving intravenous iron sucrose therapy; Group -B: 25 receiving intravenous ferric carboxymaltose therapy. Results: Majority of the study participants in Group A had gestational age between 20-25 weeks (48%). The mean age of the study participants in Group A was found to be 22.86+4.42 weeks. Majority of the study participants in Group B had gestational age between 20-25 weeks (36%). The mean age of the study participants was found to be 23.01+3.01 weeks. Majority of the study participants in Group A had nil parity (40%). 36% of the study participants in Group B had nil parity. 60% of the study participants in group A had Mild degree of anaemia with 52% in group B having mild degree of anaemia. 40% and 44% of the study participants in group A and group B had Moderate degree of anaemia respectively. The association was found to be statistically significant between the mean Hb and Ferritin values pre-treatment, 3rd and 6th week follow-up post treatment and the 2 groups of study participants. The adverse effects were comparatively lower among Group B (IV ferric carboxymaltose) than Group A (IV iron sucrose) of the study participants. Conclusions: IV ferric carboxymaltose administration increases the hemoglobin level more rapidly as compared to iron sucrose in women with iron deficiency anemia in the pregnancy. It also stores iron more rapidly. No serious adverse effects were recorded. Ferric carboxymaltose is well tolerated, safe and effective alternative to iron sucrose in iron deficiency anemia of pregnancy. FCM has the advantage of a large dose administration per sitting and early rise in hemoglobin level.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Comparative study on intravenous iron sucrose versus intravenous ferric carboxymaltose in the management of iron deficiency anaemia in pregnancy in a tertiary care hospital, Bengaluru

A¹,

MN²,

N³

2023

Int. J. Clin. Obstet. Gynaecol.

View full text Add to dashboard Cite

show abstract

“…Even the risk of allergic adverse reactions, seen with the older IV preparations, are a thing of the past. [30][31][32][33][34][35] Among iron sucrose, ferric gluconate, ferumoxytol, and FCM groups of molecules, the main difference is in pharmacokinetics, dosing, and administration requirements. [36][37][38] The expert group consensus was that FCM provides the most favorable pharmacokinetics and safety profile (it is safe even in patients with history or allergy to other drugs).…”

Section: Discussionmentioning

confidence: 99%

“…In other words, more than 70% of cancer patients are at risk of reduced OS and/or QoL because of CAA. 26…”

Section: Discussionmentioning

confidence: 99%

Practical Clinical Consensus Guidelines for the Management of Cancer Associated Anemia in Low- and Middle-Income Countries

Parikh,

Aggarwal,

Biswas

et al. 2023

South Asian J Cancer

View full text Add to dashboard Cite

Cancer-associated anemia (CAA) remains a major unmet need that compromises overall survival (OS) and quality of life (QoL). Currently, available guidelines do not take into consideration the unique challenges in low- and middle-income countries (LMIC). Our CAA patients have to battle preexisting impaired nutritional status, depleted body iron stores, financial limitations, and difficulty in having easily accessible affordable healthcare. Hence, we fulfilled the need of guidelines for LMIC. A group of subject experts were put together, given background literature, met in a face-to-face discussion, voted using Delphi process, and finally agreed on the contents of this guideline document. As many as 50% of cancer patients will have significant anemia (hemoglobin < 10 g/dL) at initial diagnosis. It is most commonly seen with gastrointestinal malignancies, head and neck cancers, and acute leukemias. The hemoglobin falls further after initiation of cancer directed therapy, due to chemotherapy itself or heightened nutritional deficiency. Its evaluation should include tests for complete blood count, red blood cell morphology, reticulocyte count, Coombs test, and levels of vitamin B12 and folic acid. Iron status should be monitored using test to measure serum iron, total iron binding capacity, transferring saturation, and serum ferritin levels. A minimum of 50% of cancer patients with anemia require iron supplements. The preferred mode of therapy is with intravenous (IV) iron using ferric carboxymaltose (FCM). Most patients respond satisfactorily to single dose of 1000 mg. It is also safe and does not require use of a test dose. Significant anemia is found in at least half of all cancer patients in India, South Asian Association for Regional Cooperation region, and other LMIC countries. Its awareness among healthcare professionals will prevent it from remaining undiagnosed (in up to 70% of all cancer patients) and adversely affecting OS and QoL. The benefits of treating them with IV iron therapy are quick replenishment of iron stores, hemoglobin returning to normal, better QoL, and avoiding risk of infections/reactions with blood transfusions. Many publications have proven the value of single-dose FCM in such clinical situations. CAA has been proven to be an independent prognostic factor that adversely affects both QoL and OS in cancer patients. Use of FCM as single IV dose of 1000 mg is safe and effective in the majority of patients with CAA.

show abstract

Effect of IV ferric carboxy maltose for moderate/severe anemia: a systematic review and meta-analysis

Khatib,

Sinha,

Gaidhane

et al. 2024

Front. Med.

View full text Add to dashboard Cite

IntroductionAnemia remains a prevalent global health issue with varying severity. Intravenous iron supplementation, particularly with ferric carboxymaltose (FCM), has appeared as a possible therapeutic intervention for individuals with moderate to severe anemia. The study aimed to assess the efficacy and safety of ferric carboxymaltose (FCM) in reducing anemia.MethodsWe searched electronic databases, registries, websites, e-libraries, reference lists of reviews, citations, etc. We included randomized control trials (RCTs), non-RCTs, and single-arm studies, while observational studies, case series, and case studies were excluded. Two reviewers independently screened the studies and extracted the data. We included studies of moderate-to-severely anemic Indians and excluded Indians with other comorbidities. We assessed the risk of bias and the overall quality of evidence (QoE) using GRADE GDT.ResultWe identified 255 studies and included 14 studies (11 RCT, one non-RCT, and two single-arm studies) with 1,972 participants for qualitative analysis and 10 studies in the meta-analysis. All the included studies detailed the use of FCM for anemia. The primary outcomes assessed in the included studies were anemia, hemoglobin, and adverse events. The outcomes assessed ranged from 2 weeks to 12 weeks. The risk of bias varied across different studies with different outcomes. FCM is consistent with a fewer number of adverse events as compared to other interventions and provides “moderate” to “very low” QoE.ConclusionA slow single infusion of 1 gram of FCM is well-tolerated, safe, and effective in treating iron deficiency anemia (IDA) and surpasses other interventions (Iron Sucrose Complex (ISC), Iron sucrose, and ferrous ascorbate) in elevating hemoglobin levels and replenishing iron stores.Systematic Review Registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?RecordID=459363, CRD42023459363.

show abstract

Intravenous ferric carboxymaltose versus iron sucrose in iron deficiency anemia of pregnancy

Cited by 3 publications

References 14 publications

Comparative study on intravenous iron sucrose versus intravenous ferric carboxymaltose in the management of iron deficiency anaemia in pregnancy in a tertiary care hospital, Bengaluru

Comparative study on intravenous iron sucrose versus intravenous ferric carboxymaltose in the management of iron deficiency anaemia in pregnancy in a tertiary care hospital, Bengaluru

Practical Clinical Consensus Guidelines for the Management of Cancer Associated Anemia in Low- and Middle-Income Countries

Effect of IV ferric carboxy maltose for moderate/severe anemia: a systematic review and meta-analysis

Contact Info

Product

Resources

About